Table 2 Immune-related adverse events
From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
| irAE | Grades 1/2 (N, %) | Grades 3/4 (N, %) |
|---|---|---|
| Arthralgias | 1 (4 %) | 0 |
| Colitis | 0 | 1 (4 %) |
| Conjunctivis | 1 (4 %) | 0 |
| Diarrhea | 1 (4 %) | 0 |
| Hepatitis | 0 | 2 (7 %) |
| Hypothyroidism | 4 (15 %) | 0 |
| Nephritis | 2 (7 %) | 0 |
| Pruritis | 1 (4 %) | 0 |
| Rash | 3 (11 %) | 0 |
| Vitiligo | 1 (4 %) | 0 |